Medigen shares COVID vaccine tech with WHO in world-first deal

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Medigen shares COVID vaccine tech with WHO in world-first deal

covid.jpg

The Taiwanese biotech firm is the first commercial entity to share IP and know-how via a WHO pool set up in 2020

Taiwanese biotech firm Medigen yesterday, August 29, became the first commercial entity to share COVID vaccine technology with the World Health Organization.

Medigen’s vaccine unit was among three licensors to share tech via the WHO’s COVID-19 Technology Access Pool (C-TAP) in new deals, alongside research institutes in Spain and Chile.

The deals involve the licensing of patents as well as the sharing of know-how, materials, and clinical data.

More than three million doses of Medigen's vaccine have been administered across seven countries.

The Spanish National Research Council (CSIC) agreed to share access to a COVID vaccine prototype while the University of Chile will share tech for a COVID antibody test.

“COVID-19 is here to stay, and the world will continue to need tools to prevent it, test for it and treat it,” said Tedros Adhanom Ghebreyesus, WHO director-general.

“I am grateful to the leadership shown by those licence holders who have contributed technology,” he added.

Charles Chen, CEO of Medigen Vaccine Biologics, said solidarity and cooperation were the foundations of an effective pandemic response.

“This is not just about COVID-19; it is about setting a precedent for future global health challenges.

“We hope to inspire other organisations to follow suit,” Chen said.

Previously, only two public health institutes – the CSIC, which signed a separate deal with C-TAP in 2021, and the US National Institute of Health – had agreed to license tech through the WHO pool since it was set up in 2020.

Access to medicine campaigners welcomed the news as a “significant step” and urged major COVID vaccine makers to share their intellectual property.

Julia Kosgei, policy co-lead for campaign group the People’s Vaccine Alliance, said: “By sharing technology with C-TAP, these organisations are placing the needs of humanity over the narrow perception of profit and self-interest that has so far plagued the pharmaceutical industry.”

“It is shameful that, despite receiving unprecedented public funding and advance purchases, not even one of the major pharmaceutical companies has shared vaccine technology with C-TAP,” Kosgei added.

Negotiations for a pandemic prevention treaty, including potential reforms to the global intellectual property system, are currently ongoing at the WHO.

more from across site and SHARED ros bottom lb

More from across our site

In an exclusive interview, Rouse CEO Luke Minford, Arnold & Siedsma managing partner Steve Duxbury, and Wrays executive chairman Gary Cox discuss plans to build the world’s first ‘truly integrated’ global IP services business
Benjamin Grzimek, partner at Casalonga’s new Düsseldorf office, believes the firm is well-placed to challenge German UPC dominance
A lot of the reporting around the Anthropic settlement misses something critical: it isn’t that relevant to AI training, argues Rebecca Newman at Addleshaw Goddard
Justin Hill and Marie Jansson Heeks, part of an 18-strong team to have joined Crowell & Moring, explain why IP client advice must go beyond only being called upon for patent disclosure
To mark the EUIPO having processed five million EUTM and REUD applications, Managing IP speaks to the most prolific representatives to uncover how they stay at the top of their game
The merger marks Rouse’s second M&A deal within a month, and will provide access to Arnold & Siedsma’s UPC offering
Simon Tønners explains why IP provides the chance to work with some of the most passionate, risk-taking, and emotionally invested clients
The co-leaders of the firm’s new SEP practice group say the team will combine litigation and prosecution expertise to guide clients through cross-border challenges
Boasting four former Spruson & Ferguson leaders and with offices in Hong Kong and Singapore, the IP firm aims to provide fast, practical advice to clients
Partners at three law firms explain why trade secrets cases are rising, and how litigation is giving clients a market advantage
Gift this article